The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...

Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more ...

Recommended Reading Guardant wins FDA approval for colon cancer blood test Exact Sciences released data from a study of its ...

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...

In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...

New data from cancer screening and diagnostic test provider Exact Sciences have shown an 88.3% sensitivity rate for its blood-based colorectal cancer screening test.

The free tests issued by the program will be viable at least through to the end of the year, with many at-home COVID tests ...